Prescribing information

 

When should you treat your patient early in MF? The rationale behind early intervention of MF is considered and the potential clinical benefits to patients are explained.

“The influence of disease stage on the quality of response, the influence of ruxolitinib dose, early intervention, higher dose, better outcome of the patients.”

Dr Verstovsek

Dr Verstovsek

 

Dr Verstovsek highlights the importance of increased knowledge surrounding MF and pre-fibrotic disease. He also helps us to understand the methods for prognostic scoring and dose optimisation in individual patients.

MF, myelofibrosis.

Rate this content: 
Average: 4 (1 vote)
UK | July 2022 | 138758
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]